Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 11/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374421 | 0.82 | RAB9A (0.51) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL20374414 | 0.82 | SNCA (0.50) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL3014652 | 0.76 | PDGFRB (0.79) | RAB9ANPC1PDGFRBPDGFRA | |
| SCHEMBL17393443 | 0.76 | RAB9A (0.58) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL1069738 | 0.75 | HPGDS (0.59) | RAB9AMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL12895918 | 0.75 | RAB9A (0.76) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL20362087 | 0.74 | PDGFRB (0.54) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL21282157 | 0.74 | S1PR1 (0.66) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL1249937 | 0.73 | MAPT (0.60) | RAB9AMEN1KMT2AHPGDNPSR1 | |
| SCHEMBL12692350 | 0.72 | NPC1 (0.86) | RAB9AMEN1KMT2AHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3565807-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129274-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129274-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | RAB9A 3468/4885MEN1 2723/4885KMT2A 1835/4885 |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | HIPK2, HIPK3, HIPK1 | RAB9A 3468/4885MEN1 2723/4885KMT2A 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.